Showing Results for
- Academic Journals (44)
Search Results
- 44
Academic Journals
- 44
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Eugenio Montini [1]; Daniela Cesana [1, 2]; Manfred Schmidt [3, 4]; Francesca Sanvito [5]; Maurilio Ponzoni [5]; Cynthia Bartholomae [4]; Lucia Sergi Sergi [1]; Fabrizio Benedicenti [1]; Alessandro Ambrosi...
- 2From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Stephanie L. Church [1] In a Texas field, five foals graze alongside matronly mares. The scene is hardly unusual, but in this pasture, there's a twist: all five youngsters are exact genetic copies of one...
- 3From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedHere's an idea. If your company is looking for a bit of extra income to support its research and clinical programs and you've gone to all your usual sources of financing and still come up short, why not trawl around to...
- 4From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): John Ransom [1] Plans for a $75-million fund specializing in biotech private equity--the IB Australian Biosciences Fund--was announced by the Australian arm of international advisory and funds management...
- 5From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Nicolas Vodovar [1]; David Vallenet [2]; Stéphane Cruveiller [2]; Zoé Rouy [2]; Valérie Barbe [2]; Carlos Acosta [1]; Laurence Cattolico [2]; Claire Jubin [2]; Aurélie Lajus [2]; Béatrice Segurens [2];...
- 6From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedFDA advisor conflicts and voting weakly linked A study in April of US Food and Drug Administration (FDA) advisory committees found that many voting members had financial ties to drug companies, but their influence did...
- 7From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Yael Weiss [1]; Avidor Shulman [2]; Irina Ben Shir [2]; Ehud Keinan (corresponding author) [2, 3]; Shmuel Wolf [1] Engineering herbicide resistance in crops facilitates control of weed species, particularly...
- 8From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Brian Vastag [1] In April, Pfizer bought a Genentech spinoff, Rinat Neuroscience, for "close to $500 million dollars," according to one source. What drew Pfizer's interest to Rinat was its pipeline, in...
- 9From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Seife Ayele [1]; Joanna Chataway [1]; David Wield [1] Eradicating extreme poverty and hunger is one of the eight millennium development goals (MDGs), with a specific target to halve hunger between 1990 and...
- 10From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Huub Schellekens [1, 2]; Wim Jiskoot [2] To the editor: In 1998, an increase in the incidence of pure red cell aplasia (PRCA) was observed that was associated with anti-erythropoietin antibodies and...
- 11From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Stephen W Michnick [1] Some of the newest ideas in modern manufacturing, like 'just in time' inventory management, were in fact invented billions of years ago by bacteria, which have been perfecting such...
- 12From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Denis Dupuy [1]; Nicolas Bertin [1]; Michael E. Cusick [1]; Jing-Dong J. Han [2]; Marc Vidal [1] Marc Vidal and colleagues respond: The distorting effect of limited sampling on the overall topology of...
- 13From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Cynthia H Collins [1]; Jared R Leadbetter [2]; Frances H Arnold (corresponding author) [1, 3] The transcription factor LuxR activates gene expression in response to binding the signaling molecule...
- 14From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Kendall Powell Nat. Biotechnol. 24, 294 (2006) In the print version of this article and the version originally published online, there is an error. On page 294, the first name of Dr. Potrykus should...
- 15From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Mary Yaroshevsky-Glanville Nat. Biotechnol. 23, 391-392 (2005) It has been brought to the attention of the author and the editors that in the print version of this article and the version originally...
- 16From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Gerard Porter [1]; Chris Denning [2]; Aurora Plomer [1]; John Sinden [3]; Paul Torremans [1] The United States Patent and Trademark Office (USPTO) has, to date, granted 41 patents that claim human...
- 17From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Caroline C. Friedel [1]; Ralf Zimmer [1] To the editor: Incomplete protein-protein interaction networks obtained in high-throughput experiments are commonly used to characterize the topology of the...
- 18From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedPrivately held Raven biotechnologies (S. San Francisco, CA, USA) has announced the appointment of George F. Schreiner (right) as CEO and director. Dr. Schreiner joins Raven from Scios, where he most recently served as...
- 19From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Clyde A Hutchison, III [1]; J Craig Venter [1] Relatively few bacterial species observed in nature have been grown in pure culture. For the vast majority of bacteria, genome sequencing has been prevented...
- 20From: Nature Biotechnology. (Vol. 24, Issue 6) Peer-ReviewedAuthor(s): Matthew J. Kleiman [1]; Laura B. Sontag [2] To the editor: Many in the scientific community are concerned that access to crucial information will be constrained by the increasing number of patents...